Phase I/II Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)
Phase of Trial: Phase I/II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Ixazomib (Primary) ; Peginterferon alfa-2b (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 14 Jun 2017 Status changed from recruiting to discontinued as closure facilitated by Investigator.
- 10 Jun 2017 Biomarkers information updated
- 25 Jan 2017 Planned End Date changed from 1 Nov 2017 to 1 Aug 2018.